CytoMed Therapeutics Limited (NASDAQ:GDTC – Get Free Report) shares were up 2.2% during trading on Thursday . The company traded as high as $2.13 and last traded at $2.11. Approximately 713 shares traded hands during trading, a decline of 98% from the average daily volume of 32,086 shares. The stock had previously closed at $2.06.
CytoMed Therapeutics Price Performance
The company’s 50-day moving average is $2.28 and its 200-day moving average is $3.29.
CytoMed Therapeutics Company Profile
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers in Malaysia and Singapore. Its lead product candidate is CTM-N2D, which is in Phase I clinical trials comprising expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor to improve anti-cancer cytotoxicity.
Read More
- Five stocks we like better than CytoMed Therapeutics
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- Here are the Pros and Cons of Using Options Call Debit Spreads
- Canadian Penny Stocks: Can They Make You Rich?
- Carmax Returns to the Bargain Basement: Buy the Dip?
- Profitably Trade Stocks at 52-Week Highs
- Dividend Aristocrat Fastenal Goes on Sale: Buy It While It’s Down
Receive News & Ratings for CytoMed Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytoMed Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
